Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Alkali metal or alkaline earth containing
Patent
1993-08-24
1995-09-12
Krass, Frederick
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Alkali metal or alkaline earth containing
424679, 424717, 424568, 514 4, 514 23, 514397, A61K 3314, A61K 3555
Patent
active
054495229
ABSTRACT:
This invention provides an immunoenhancement or immunepotentiation therapy comprising administration of potassium, insulin, glucose and, optionally, thyroid, a cholinergic agent and bicarbonate. Therapeutic compositions comprising the above components in appropriate dosages are also provided.
REFERENCES:
patent: 4196196 (1980-04-01), Tiholiz
patent: 4971951 (1990-11-01), Garcia y Bellon et al.
patent: 5077284 (1991-12-01), Loria et al.
Old, L. J. (1988), "Tumor Necrosis Factor," Scientific American 258:59-75.
Patillo, R. (1974) "Trophoblast Cancers," in Hormones and Cancer, (K. W. McKerns, ed.), Academic Press, New York, p. 363-387.
Prehn, R. T. (1976), "Do Tumors Grow because of the Immune Response of the Host.degree." Transplantation Reviews 28:34-42.
Ellenhorn, J. D. et al. (1988), "In vivo Administration of Anti-CD3 Prevents Malignant Progressor Tumor Growth," Science 242:569-571.
Golde, D. W. et al. (1988), "Hormones that Stimulate the Growth of Blood Cells," Scientific American 259:62-70.
Bevilacqua M. P. et al. (1989), "Endothelial Leukocyte Adhesion Molecule 1: an Inducible Receptor for Neutrophils Related to Complement Regulatory Proteins and Lectins," Science 243:1160.
Oppenheim, J. J. et al. (1987), in Basic and Clinical Immunology, Sixth ed., (D. P. Stites, et al., eds.), Appleton and Lange, Los Altos, CA, p. 94.
Rosenberg, S. A. et al. (1986), "A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-infiltrating Lymphocytes," Science 233:1318-1321.
Geiger, J. D. et al. (1993), "Generation of T-Cells Reactive to the Poorly Immunogenic B16-BL6 Melanoma with Efficacy in the Treatment of Spontaneous Metastases," J. Immunother. 13:153-165.
Chang, A. E. et al. (1993), "Clinical Observations on Adoptive Immunotherapy with Vaccine-primed T-Lymphocytes Secondarily Sensitized to Tumor In Vitro," Cancer Res. 53:1043-1050.
Handwerger, B. S. and Douglas, S. D., (1980) "The Cell Biology of Blastogenesis," in The Cell Biology of Inflammation, (G. Weismann, ed.), Elsevier, New York/N. Holland Biomedical Press, Amsterdam, p. 652-657.
Lawrence, T. S. and Davis, M. A. (1990), "The Influence of Na.sup.+, K.sup.+ -pump Blockade on Doxorubicin-mediated Cytotoxicity and DNA Strand Breakage in Human Tumor Cells," Cancer Chemother. and Pharmacol. 26:163-67.
Owens, T. and Kaplan, J. G. (1981), "Monovalent Cation Fluxes in Activated Mouse T- and B-Lymphocytes," in Mechanisms of Lymphocyte Activation (Resch, K. and Kirchner, H. eds.) pp. 238-241.
Grinstein, S. and Dixon, S. J. (1989), "Ion Transport, Membrane Potential, and Cytoplasmic pH in Lymphocytes: Changes during Activation," Physiol. Rev. 69:417-481.
Cahalan, M. D. et al. (1991), "Potassium Channels in Development, Activation, and Disease in T-Lymphocytes," in Developmental Biology of Membrane Transport Systems (Benos, D. J., ed.), pp. 357-394.
Gerson, M., A Cancer Therapy: Results of Fifty Cases, (New York: Dura Books, Inc., 1958), pp. 237-248.
Edgington, S. M. (1993), "Looking Death in the Eye: Apoptosis and Cancer Research--Is Cancer really Caused by Cells Refusing to Commit Suicide on Cue?," Bio/Tech. 11:787-792.
Hardin, J. A., et al., (1992), "A Simple Fluorescence Method for Surface Antigen Phenotyping of Lymphocytes Undergoing DNA Fragmentation," J. immuno. Meth. 154:99-107.
Ojcius, D. M., et al. (1991), "Ionophore-Induced Apoptosis: Role of DNA Fragmentation and Calcium Fluxes," Exp. Cell. Res. 197:43-49.
McGrady, P. (1964), The Savage Cell, Basic Books, Inc., New York, p. 138-140.
Kassirer, Jerome P., (1989), "Repairing Body Fluids: Principles and Practice," p. 46-72.
Koffler, Michael, et al. (1991), "Immunobiological Consequence of Regulation of Insulin Receptor on Alloactivated Lymphocytes in Normal and Obese Subjects," Diabetes 40:364-370.
Coffey, Ronald G. and Hadden, John W. (1984), "Cyclic Nucleotides in Neurohumoral and Hormonal Regulation of Cells of the Immune System," in Stress, Immunity and Aging (Cooper, E. L., ed.) pp. 231 ff.
Strom, Terry B., et al. (1975), "Insulin-Induced Augmentation of Lymphocyte-Mediated Cytotoxicity," Science 187:1206-1208.
Ercolani, L., et al. (1985), "Insulin-Induced Desensitization at the Receptor and Postreceptor Level in Mitogen-Activated Human T-lymphocytes," Diabetes: 34:931-937.
Morrison, S. D. (1982), "Feeding Responcse of Tumor-bearing Rats to Insulin Withdrawl and the Contribution of Autonomous Tumor Drain to Cachectic Depletion," Cancer Res. 42:3642-3647.
Moley, J. F., et al. (1985), "Insulin Reversal of Cancer Cachexia in Rats," Cancer Res. 45:4925-4931.
Moley, J. F., et al. (1983), "Effects of Exogenous Insulin Administration on Food Intake, Body Weight Change, and Tumor Doubling Time," Surgical Forum 35:91-93.
Schein, Philip S., et al. (1979) "Cachexia of Malignancy," Cancer 43:2070-2076.
Strom, T. B., et al. (1977), "The Role of Cyclic Nucleotides in Lymphocyte Activation and Function," in Progress in Clinical Immunology (Schwartz, R. S., ed.) at 115-153.
Ignarro, L. J. and Cech, S. Y. (1976), "Bidirectional Regulation of Lysosomal Enzyme Secretion and Phagocytosis in Human Neutrophils by Guanosine 3', 5'-Monophosphate and Adenosine 3', 5'-Monophosphate (39232)," Proc. Nat. Acad. Sci. 151:448-452.
Unanue, E. R. and Schreiner, G. F. (1975), "The Modulation of Immunoglobulin in B Lympocytes and its Relevance to Immune Stimulation," Immune Recognition (Rosenthal, A. S., ed.) at 261-280.
Kasner, S. E. and Ganz, M. B. (1992), "Regulation of intracellular potassium in mesangeal cells: a fluorescence analysis usin the dye, PBFI," Amer. J. Physiol. 3:462-467.
Provinciali, M., et al. (1992), "Optimization of Cytoxic Assay by Target Cell Retention of the Fluorescent Dye Carboxyfluorescein Diacetate (CFDA) and Comparison with Conventional.sup.51 Cr Release Assay," J. Immunol. Meth. 155:19-24.
Vollenweider, I. and Groseurth, P. J. (1992), "Comparison of the Four DNA Staining Fluorescence Dyes for Measuring Cell Proliferation of Lymphokine-activated killer LAK) Cells," J. Immunol. Meth. 149:133-135.
Loeffler, D. A., et al. (1992), "Analysis of Distribution of Tumor- and Preneoplasia-Infiltrating Lymphocytes Using Simultaneous Hoechst 33342 Labeling and Immunophenotyping," Cytom. 13:169-174.
Rivoltini, L., et al (1992), "Phenotypic and Functional Analysis of Lymphocytes Infiltrating Paediatric Tumours, with a Characterization of the Tumour Phenotype," Can. Immunol. Immunother. 34:241-251.
Harold, F. M. (1986) The Vital Force: A Study of Bioenergetics, W. H. Freeman and Co., New York, pp. 325-326.
Segel, G. B. and Lichtman, M. A. (1976), "Potassium Transport in Human Blood Lymphocytes Treated with Phytohemagglutinin," J, Clin. Investigation 58:1358-1359; 1365-1366.
Quastel, M. R. and Kaplan, J. G. (1970) "Early Stimulation of Potassium Uptake in Lymphocytes Treated with PHA," Expl. Cell. Res. 63:230-233.
Ignarro, L. J. (1975), "Regulation of Lysosomal Enzyme Release by Prostaglandins, Autonomic Neurohormones and Cylic Nucleotides," in Lysosomes in Biology and Pathology (Dingle, J. T. and Dean, R. T., eds.) pp. 481-523.
Hadden, J. W. (1987), "Neuroendocrine Modulation of the Thymus-Dependent Immune System," Annals of the N.Y. Acad. of Sciences 496:39-48.
Tiedt, T. N. et al. (1979) "Voltage- and Time-Dependent Actions of Piperocaine on the Ion Channel of the Acetylcholine Receptor," Molec. Pharmacology 16:909-921.
Rosenberg, S. A. (1990), "Adoptive Immunotherapy for Cancer," Scientific American 262:62-69.
Hulina Amy
Krass Frederick
LandOfFree
Pharmaceutical composition for immunoenhancement therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for immunoenhancement therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for immunoenhancement therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-404221